Microbot has expanded a collaboration with Corewell Health to evaluate its Liberty endovascular robotic system in remote telesurgery applications.
The agreement, which has advanced into a second phase, will see simulated cardiovascular interventional procedure capabilities developed across two sites within the Corewell Health system.
Go deeper with GlobalData
The agreement with Corewell Health, which is Michigan’s largest healthcare system, includes the right to mutually evaluate the Liberty system.
US-based Microbot’s Liberty system is a single-use endovascular surgical robot designed to remove the need for large and expensive capital equipment. The technology is being evaluated in the LIBERTY study under an investigational device exemption (IDE), awarded by the US Food and Drug Administration (FDA) in June 2024. The company wrapped up clinical trial site enrolment for the study last month.
Microbot reported positive results from the first phase in April, with collaboration lead Dr Ryan Madder publishing an abstract in the Journal of the American College of Cardiology. The study, conducted in an ex vivo coronary model, saw the robot deliver a guidewire and stent to target locations in vasculature. In some attempts, the operating physician was in a separate room 12m from the robot. The paper reported a 100% success rate, meaning future in vivo studies could be on the horizon.
Advantages of telesurgery include radiation safety and remote care benefits, though critics say that it fails to provide tactile information feedback.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMicrobot’s CEO Harel Gadot said: “Incorporating telesurgery capabilities is an important part of our long-term strategy for Liberty. We believe that physicians in the US and around the globe want to increase access to care for patients in remote locations.”
The robotic surgical systems market is projected to grow from $3.3bn in 2023 to $7.2bn in 2033, with a compound annual growth rate (CAGR) of 15.7%, according to GlobalData analysis. The growth of the market is attributed to a push for less-invasive procedures in a growing elderly population.
The clinical trial space for surgical robots is advancing – J&J MedTech is eyeing an entry into the space. The company said it plans to submit an investigational device exemption application to the FDA in the latter half of 2024. Approval would allow the robot, which can be incorporated into any operating room, to be used in clinical trials later this year.
